PARD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PARD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Poniard Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $1.64 Mil. Poniard Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2011 was $-13.75 Mil. Poniard Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2011 was -0.12.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Poniard Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
The historical data trend for Poniard Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poniard Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec01 | Dec02 | Dec03 | Dec04 | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.82 | -0.32 | -0.53 | -0.52 | -0.06 |
Poniard Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec06 | Mar07 | Jun07 | Sep07 | Dec07 | Mar08 | Jun08 | Sep08 | Dec08 | Mar09 | Jun09 | Sep09 | Dec09 | Mar10 | Jun10 | Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.64 | -0.09 | -0.14 | -0.12 | -0.12 |
For the Biotechnology subindustry, Poniard Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Poniard Pharmaceuticals's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Poniard Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2010 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0 | + | 1.574) | / | -25.019 | |
= | -0.06 |
Poniard Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2011 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0 | + | 1.64) | / | -13.748 | |
= | -0.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2011) EBITDA data.
Poniard Pharmaceuticals (OTCPK:PARD) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S Perry | officer: President & CMO | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Ron Martell | director, officer: Chief Executive Officer | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
David R Stevens | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Fred B Craves | director | 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111 |
Simon Nicholas J Iii | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Gregory L Weaver | officer: Chief Financial Officer | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
Kurt Wheeler | 10 percent owner | 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080 |
Mpm Asset Management Investors 2005 Bviii Llc | 10 percent owner | C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199 |
Nicholas Galakatos | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Dennis Henner | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Michael Steinmetz | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Luke Evnin | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
From GuruFocus
By gurufocus • 05-12-2009
By gurufocus 10qk • 11-09-2010
By gurufocus 10qk • 08-09-2010
By gurufocus • 04-06-2009
By GuruFocus Research GuruFocus Editor • 08-22-2009
By gurufocus 10qk • 05-10-2010
By gurufocus • 08-07-2009
By gurufocus 10qk • 11-06-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.